CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs

CRISPR Therapeutics AG

2024-Q2 EPS reported -$2.92 revenue$1,021,000

Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.
Cash, equivalents and securities $2.01B as of June 30, up from $1.70B at Dec 31, 2023.
CASGEVY: >35 ATCs activated globally; ~20 patients have had cells collected as of mid-July.
CTX112 CD19 CAR T Phase 1/2 trial opened for SLE; preliminary oncology data expected this year.
Appointed Naimish Patel as CMO; promoted Julianne Bruno to COO and Susan Kim to SVP IR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.